Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, California 92093, USA.
J Biol Chem. 2010 Apr 23;285(17):12765-77. doi: 10.1074/jbc.M109.045161. Epub 2010 Feb 15.
Although several non-receptor activators of heterotrimeric G proteins have been identified, the structural features of G proteins that determine their interaction with such activators and the subsequent biological effects are poorly understood. Here we investigated the structural determinants in G alpha(i3) necessary for its regulation by GIV/girdin, a guanine-nucleotide exchange factor (GEF) that activates G alpha(i) subunits. Using G protein activity and in vitro pulldown assays we demonstrate that G alpha(i3) is a better substrate for GIV than the highly homologous G alpha(o). We identified Trp-258 in the G alpha(i) subunit as a novel structural determinant for GIV binding by comparing GIV binding to G alpha(i3)/G alpha(o) chimeras. Mutation of Trp-258 to the corresponding Phe in G alpha(o) decreased GIV binding in vitro and in cultured cells but did not perturb interaction with other G alpha-binding partners, i.e. G betagamma, AGS3 (a guanine nucleotide dissociation inhibitor), GAIP/RGS19 (a GTPase-activating protein), and LPAR1 (a G protein-coupled receptor). Activation of G alpha(i3) by GIV was also dramatically reduced when Trp-258 was replaced with Tyr, Leu, Ser, His, Asp, or Ala, highlighting that Trp is required for maximal activation. Moreover, when mutant G alpha(i3) W258F was expressed in HeLa cells they failed to undergo cell migration and to enhance Akt signaling after growth factor or G protein-coupled receptor stimulation. Thus activation of G alpha(i3) by GIV is essential for biological functions associated with G alpha(i3) activation. In conclusion, we have discovered a novel structural determinant on G alpha(i) that plays a key role in defining the selectivity and efficiency of the GEF activity of GIV on G alpha(i) and that represents an attractive target site for designing small molecules to disrupt the G alpha(i)-GIV interface for therapeutic purposes.
虽然已经鉴定出几种非受体激活异三聚体 G 蛋白的物质,但决定 G 蛋白与其相互作用以及随后的生物学效应的结构特征仍知之甚少。在这里,我们研究了 Gαi3 中使其受 GIV/girdin 调节的结构决定因素,GIV/girdin 是一种激活 Gαi 亚基的鸟嘌呤核苷酸交换因子 (GEF)。使用 G 蛋白活性和体外下拉测定法,我们证明 Gαi3 是 GIV 的比高度同源的 Gαo 更好的底物。通过比较 GIV 与 Gαi3/Gαo 嵌合体的结合,我们确定 G 蛋白亚基中的色氨酸 258 是 GIV 结合的新结构决定因素。将 Gαo 中的色氨酸 258 突变为苯丙氨酸,不仅降低了 GIV 的体外结合,也降低了 GIV 在培养细胞中的结合,但并未干扰与其他 G 蛋白结合伙伴的相互作用,即 Gβγ、AGS3(鸟嘌呤核苷酸解离抑制剂)、GAIP/RGS19(GTPase 激活蛋白)和 LPAR1(G 蛋白偶联受体)。当用 Tyr、Leu、Ser、His、Asp 或 Ala 替换 Gαi3 中的色氨酸 258 时,GIV 对 Gαi3 的激活作用也显著降低,这突出表明色氨酸是最大激活所必需的。此外,当突变的 Gαi3 W258F 在 HeLa 细胞中表达时,它们无法进行细胞迁移,并在生长因子或 G 蛋白偶联受体刺激后增强 Akt 信号。因此,GIV 对 Gαi3 的激活对于与 Gαi3 激活相关的生物学功能是必不可少的。总之,我们发现了 Gαi 上的一个新的结构决定因素,它在确定 GIV 对 Gαi 的 GEF 活性的选择性和效率方面起着关键作用,并且代表了一个有吸引力的靶标位点,可用于设计小分子以破坏用于治疗目的的 Gαi-GIV 界面。